Carcinoid Tumors
June 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Carcinoid Tumors abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Carcinoid Tumors. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Carcinoid Tumors. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Carcinoid Tumors every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Pancreatic carcinoids (serotonin-producing pancreatic neuroendocrine neoplasms): Report of 5 cases and review of the literature.
Authors:Tsoukalas N, Chatzellis E, Rontogianni D, Alexandraki KI, Boutzios G, Angelousi A, Kaltsas G
Institution:aDepartment of Medical Oncology, "401" General Military Hospital bEndocrine Unit, Department of Pathophysiology, National University of Athens cPathology Department, Evangelismos Hospital, Athens, Greece.
Journal:Medicine (Baltimore). 2017 Apr;96(16):e6201. doi: 10.1097/MD.0000000000006201.

2:Telotristat Ethyl: First Global Approval.
Authors:Markham A
Institution:Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Journal:Drugs. 2017 May;77(7):793-798. doi: 10.1007/s40265-017-0737-x.

3:Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Authors:Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC
Institution:Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Center, Houston, TX, USA; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Cancer Center, Houston, TX, USA. Center, Houston, TX, USA. Center, Houston, TX, USA. Houston, TX, USA. Center, Houston, TX, USA. Cancer Center, Houston, TX, USA. Electronic address: jyao@mdanderson.org.
Journal:Lancet Oncol. 2017 Apr;18(4):525-534. doi: 10.1016/S1470-2045(17)30110-9. Epub 2017 Feb 24.

4:Sphenoid sinus carcinoid tumour causing ectopic ACTH syndrome.
Authors:Perera S, Taha A
Institution:Department of Neurosurgery, Dunedin Public Hospital, Dunedin, New Zealand. Electronic address: pererasanjaya@gmail.com. Electronic address: Ahmad.Taha@southerndhb.govt.nz.
Journal:J Clin Neurosci. 2017 May;39:92-95. doi: 10.1016/j.jocn.2017.01.023. Epub 2017 Feb 12.

5:CT and MRI findings of thymic carcinoid.
Authors:Shimamoto A, Ashizawa K, Kido Y, Hayashi H, Nagayasu T, Kawakami A, Mukae H, Hayashi T, Ohtsubo M, Shigematsu K, Nakazono T, Yabuuchi H, Uetani M
Institution:1 Department of Radiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Biomedical Sciences, Nagasaki, Japan. Sciences, Nagasaki, Japan. Sciences, Nagasaki, Japan. Biomedical Sciences, Nagasaki, Japan. Biomedical Sciences, Nagasaki, Japan. Japan. Nagasaki, Japan. Nagasaki, Japan. University, Fukuoka, Japan. Sciences, Nagasaki, Japan.
Journal:Br J Radiol. 2017 Mar;90(1071):20150341. doi: 10.1259/bjr.20150341. Epub 2017 Jan 20.

6:Second malignancy risk in patients with bronchopulmonary carcinoids: epidemiological results from Italian Network of Cancer Registries.
Authors:Lococo F, Galeone C, Sacchettini C, Leuzzi G, Cesario A, Paci M, Mangone L
Institution:Unit of Thoracic Surgery, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia - Italy. Italy. Italy. Gemelli, Rome - Italy. Italy. Reggio Emilia - Italy.
Journal:Tumori. 2017 Mar 24;103(2):e15-e20. doi: 10.5301/tj.5000598.

7:Metastatic carcinoid tumor to the breast: report of two cases and review of the literature.
Authors:Lee S, Levine P, Heller SL, Hernandez O, Mercado CL, Chhor CM
Institution:New York University School of Medicine. Electronic address: Shimwoo.Lee@med.nyu.edu. NY, USA. Electronic address: Pascale.Levine@nyumc.org. NY, USA. Electronic address: Samantha.Heller@nyumc.org. NY, USA. Electronic address: Osvaldo.Hernandez@nyumc.org. NY, USA. Electronic address: Cecilia.Mercado@nyumc.org. NY, USA. Electronic address: Chloe.Chhor@nyumc.org.
Journal:Clin Imaging. 2017 Mar - Apr;42:88-92. doi: 10.1016/j.clinimag.2016.10.011. Epub 2016 Oct 17.

8:Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours.
Authors:Clay V, Papaxoinis G, Sanderson B, Valle JW, Howell M, Lamarca A, Krysiak P, Bishop P, Nonaka D, Mansoor W
Institution:Department of Medical Oncology, The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK. Road, Manchester, M20 4BX, UK. Road, Manchester, M20 4BX, UK. Road, Manchester, M20 4BX, UK. Road, Manchester, M20 4BX, UK. Road, Manchester, M20 4BX, UK. Manchester, M23 9LT, UK. Manchester, M23 9LT, UK. 4BX, UK. Road, Manchester, M20 4BX, UK. Was.Mansoor@christie.nhs.uk. Was.Mansoor@christie.nhs.uk.
Journal:Clin Transl Oncol. 2017 May;19(5):579-586. doi: 10.1007/s12094-016-1568-z. Epub 2016 Nov 15.

9:Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
Authors:Swarts DR, Rudelius M, Claessen SM, Cleutjens JP, Seidl S, Volante M, Ramaekers FC, Speel EJ
Institution:Department of Molecular Cell Biology, Maastricht University Medical Center, Maastricht, the Netherlands. Maastricht, the Netherlands. Maastricht University Medical Center, Maastricht, the Netherlands. Hospital, Orbassano, Turin, Italy. Maastricht, the Netherlands. Maastricht University Medical Center, Maastricht, the Netherlands.
Journal:Histopathology. 2017 Feb;70(3):412-422. doi: 10.1111/his.13096. Epub 2016 Nov 23.

10:Spontaneous Regression of Endobronchial Carcinoid Tumor.
Authors:Venkatram S, Sinha N, Hashmi H, Niazi M, Diaz-Fuentes G
Institution:*Division of Pulmonary and Critical Care Medicine double daggerDepartment of Pathology, Albert Einstein College of Medicine, Bronx Lebanon Hospital Center daggerDivision of Pulmonary and Critical Care Medicine, Bronx Lebanon Hospital Center, Bronx, NY.
Journal:J Bronchology Interv Pulmonol. 2017 Jan;24(1):70-74.

11:Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease.
Authors:Silaschi M, Barr J, Chaubey S, Nicou N, Srirajaskanthan R, Byrne J, Ramage J, MacCarthy P, Wendler O
Institution:Department of Cardiothoracic Surgery, King's College Hospital, London, UK.
Journal:Neuroendocrinology. 2017;104(3):257-263. doi: 10.1159/000446213. Epub 2016 Apr 21.

For a FREE PREVIEW of the Medifocus Guidebook on Carcinoid Tumors click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Carcinoid Tumors click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Carcinoid Tumors...
at a Special 20% Discount


Medifocus Guidebook on Carcinoid Tumors

Updated: June 20, 2017
151 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Carcinoid Tumors is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CT52540919

Coupon Expires: August 25, 2017



What Our Customers Are Saying...

"The MediFocus Guidebook on Carcinoid Tumors helped me prepare for my operation. It was reassuring to be able to communicate with my surgeon and the consulting doctors having knowledge about my condition."
P.T.
Newcastle, England


"The Guide is detailed and written in a way that the layman can readily understand. My wife, who has just had a Carcinoid Tumor removed, is reading it as I write this. It will be helpful in her recovery and ongoing therapy."
F.B.
Nanaimo, British Columbia


"The MediFocus Guidebook on Carcinoid Tumors was extremely informative and easy to understand. Now I'm able to discuss my condition with my doctor in an informed manner and make better decisions regarding my treatment."
J.P.F.
Agoura Hills, California



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.